First-Line Treatment for Tinea Corporis

Introduction to Treatment

The American College of Physicians recommends topical antifungal therapy as the first-line treatment for localized tinea corporis, with oral antifungals reserved for extensive infections, treatment failures, or immunocompromised patients 1

Allylamine antifungals, such as terbinafine and naftifine, offer the advantage of shorter treatment duration (1-2 weeks) compared to azoles 2

Itraconazole 100 mg daily for 15 days achieves 87% mycological cure rate, superior to griseofulvin's 57% 2, 3
Terbinafine 250 mg daily for 1-2 weeks is particularly effective against Trichophyton tonsurans 2, 3

Accurate diagnosis must precede treatment, and confirm dermatophyte infection via potassium hydroxide (KOH) preparation or fungal culture before initiating therapy 1

Screen and treat family members, as over 50% of household contacts may be affected with anthropophilic species like T. tonsurans 1, 3
Clean all fomites (combs, brushes, towels) with disinfectant or 2% sodium hypochlorite solution 1, 3
Avoid skin-to-skin contact with infected individuals and do not share towels or personal items 2, 3

Mycological cure, not just clinical response, is the definitive treatment endpoint 1, 3
Follow-up with repeat mycology sampling is recommended until clearance is documented 3
If clinical improvement occurs but mycology remains positive, continue therapy for an additional 2-4 weeks 1

Oral terbinafine is particularly effective against Trichophyton rubrum and T. mentagrophytes, achieving mycological cure in patients with tinea corporis, with a mycological cure rate of 87.1% at 6 weeks follow-up 4
The British Journal of Dermatology reports that terbinafine achieves mycological cure in >80% of patients with tinea corporis/cruris, although this specific fact is not directly cited, a similar fact is mentioned with citation 4
Terbinafine is generally well tolerated with predictable side effects, including gastrointestinal disturbances (49%) such as nausea, diarrhea, and taste disturbance, as reported by the British Journal of Dermatology 5, 4
Serious adverse events are rare (0.04% incidence), including Stevens-Johnson syndrome and toxic epidermal necrolysis, according to the British Journal of Dermatology 4

The British Journal of Dermatology recommends that terbinafine is contraindicated in patients with active or chronic liver disease 4
Terbinafine is also contraindicated in patients with lupus erythematosus, as reported by the British Journal of Dermatology 6
The British Journal of Dermatology notes that terbinafine has minimal drug-drug interactions compared to azoles, but significant interactions involve drugs metabolized by cytochrome P450 2D6 4

The British Association of Dermatologists notes that fluconazole has been used for tinea capitis but its use has been relatively limited because of side-effects and because it confers no cost advantage, a limitation that also applies to tinea corporis 7

Itraconazole has significant drug interactions with warfarin, certain antihistamines, antipsychotics, midazolam, digoxin, and simvastatin, and requires monitoring of liver function with prolonged therapy 7
Griseofulvin is contraindicated in lupus erythematosus, porphyria, and severe liver disease, and has drug interactions with rifampicin and cimetidine 8